目的：探讨细胞因子诱导的杀伤（cytokine-induced killer，CIK）细胞联合化疗对胃癌患者的疗效。方法：计算机检索PubMed、EMBase、Web of Science、Cochrane数据库、中国期刊全文数据库和维普数据库，收集1990年1月到2014年3月发表的符合要求的随机对照试验或非随机同期对照试验，应用Revman 5.2软件进行Meta分析。结果：共纳入5项研究、306名胃癌患者。Meta分析结果提示，与单纯化疗相比，CIK细胞联合化疗能够提高患者近、远期疗效。肿瘤近期缓解率：RR=214，95% CI: 1.20~3.79， P =0.01， I 2=0 %。远期效应：1年存活率，RR=1.13，95% CI: 1.03~1.24， P =0.09， I 2=50%；2年存活率，RR=1.22，95% CI: 1.11~ 1.44， P =0.46， I 2= 0 %；3年存活率，RR=1.34，95% CI: 1.10~1.63， P =0.5， I 2=0%。无进展生存期：RR= 2.65，95% CI:2.29~3.01， P <0.001， I 2=98%。结论：CIK细胞联合化疗相对于单纯化疗能提高胃癌患者近、远期疗效，延长患者无进展生存期。

Objective: To evaluate the effectiveness of chemotherapy combined with adoptive transfer of cytokine-Induced killer cells (CIK) in the treatment of gastric cancer. Methods: We searched for randomized controlled clinical trials of gastric cancer treatment in PubMed, EMBASE, Web of Science, Chorane, CNKI, and VIP database from January 1990 to March 2014. Meta analysis was performed with the Revman 5.2 software. Results: We found 5 studies that enrolled 306 patients met the criteria. Analysis of the data indicated that, compared with chemotherapy alone, chemotherapy combined with adoptive transfer of CIK in the treatment of gastric cancer improved the short and long term responses. The detail short term remission rate and long term (1, 2, and 3 years) survival rates are as follow: short term （RR=2.14，95% CI: 1.20~ 3.79， P =0.01， I 2=0%）, 1-year (RR=1.13，95% CI: 1.03~1.24， P =0.09， I 2=50%), 2-year（RR=1.22，95% CI: 1.11~1.44， P =0.46， I 2=0%), 3-year（RR=1.34，95% CI: 1.10~1.63， P =0.5， I 2=0%）. The combined therapy also significant prolonged the progress-free survival of patients (RR= 2.65，95% CI：229~3.01\]， P <0.001， I 2=98%). Conclusion: Chemotherapy combined with adoptive transfer of CIK can improve the overall response and progress-free survival of gastric cancer patients.

军队“十二五”医药卫生科研基金重点资助项目（No.BWS12J051）。